¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative growth"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • apical growth
    ³¡¼ºÀå
  • appositional growth
    µ¡ºÙÀ̼ºÀå, ºÎ°¡¼ºÀå
  • asymmetric fetal growth restriction
    ºñ´ëĪžƼºÀåÁ¦ÇÑ
  • asynchronous growth
    ºñµ¿±âÁõ½Ä
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
  • bacterial growth rate
    ¼¼±ÕÁõ½Ä·ü
  • catch-up growth
    µû¶óÀâÀ̼ºÀå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • time dependent relative risk model
    ½Ã°£ÀÇÁ¸»ó´ëÀ§Çè¸ðµ¨
  • relative odds
    »ó´ëÀû´ëÀÀºñ
  • relative magnetic permeability
    »ó´ëÀÚ±âÅõ°ú·Â
  • relative refractory period
    »ó´ëºÒÀÀ±â
  • relative
    °ü°è
  • relative risk
    ºñ±³À§Çèµµ
  • relative scotoma
    »ó´ë¾ÏÁ¡
  • relative sterility
    »ó´ëÀûºÒÀÓ(Áõ)
  • relative biologic biologic effectiveness radiation
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • relative osteoid volume
    »ó´ëÀ¯°ñ·®
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • resource based relative value scale
    Áö¿ø±âÁØ»ó´ë°¡Ä¡
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • anchorage independent growth
    ºñºÎÂøÁõ½Ä, ºñºÎÂø¹ßÀ°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative hearing
    »ó´ë(Àû) û°¨
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
  • relative immunity
    »ó´ë¸é¿ª(¡­Øóæ¹).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£)
  • relative error
    »ó´ë¿ÀÂ÷(Ë×ËÀËí̤).
  • relative field
    ºñ±³¿µ¿ª(ÝïÎòçÐæ´).
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ(ËÓË´Ë×̬).
  • relative hearing
    »ó´ë(Àû) û°¨
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£).
  • relative hepatic dullness
    »ó´ë°£Å¹À½°è(ßÓÓßÊÜöúëåÍ£)
  • relative humidity
    »ó´ë½Àµµ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • balanced growth
    ±ÕÇü¼ºÀå(гû¬à÷íþ)
  • chain-growth polymer
    »ç½½½ÅÀå(ãßíþ)ÁßÇÕü(ñìùêô÷)
  • comb growth test
    °è°ü ¼ºÀå½ÃÇè(ͮήà÷íþãËúÐ)
  • confluent growth
    Àü¸é¼ºÀå(îïØüà÷íþ)
  • density-dependent growth
    "¹ÐµµÀÇÁ¸ ¼ºÀå(ÚËÓøëîðíà÷íþ), (ÔÒ) contact inhibition"
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
  • exponential growth
    Áö¼ö ¼ºÀå (ò¦â¦à÷íþ)
  • exponential growth rate constant
    Áö¼ö ¼ºÀå¼Óµµ »ó¼ö (ò¦â¦à÷íþáÜÓøßÈâ¦)
  • fibroblast growth factors
    ¼¶À¯¾Æ¼¼Æ÷ ¼ºÀÚÀÎÀÚ (àéë«ä´á¬øàà÷íþì×í­)
  • growth curve
    ¼ºÀå°î¼± (à÷íþÍØàÊ)
  • growth factor
    ¼ºÀåÀÎÀÚ (à÷íþì×í­)
  • growth hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó
  • growth hormone regulatory hormone
    ¼ºÀå(à÷íþ)È£¸£¸ó Á¶Àý(ðàï½) È£¸£¸ó
  • growth hormone release-inhibiting hormone
    ¼ºÀå(à÷íþ) È£¸£¸ó ¹æÃâÀúÇØ (Û¯õóîÁúª) È£¸£¸ó
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RSA rabbit serum albumin; regular spiking activity; relative specific activity; relative standard accura...
RGR relative growth rate
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
GD gastroduodenal; Gaucher disease; general diagnostics; general dispensary; gestational day; Gianotti ...
GF gastric fistula; gastric fluid; germ-free; glass factor; glomerular filtration; gluten-free; grandfa...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
FDR first degree relative
HRR Haplotype Relative Risk
HHRR Haplotype-based Haplotype Relative Risk
MRDR Modified Relative Dose Response
ROC Relative Operating Characteristic
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone growth
    °ñ ¼ºÀå
    »ÀÀÇ Å©±â°¡ Áõ°¡ÇÏ´Â °ÍÀ¸·Î bone maturation
  • catch-up growth
    µû¶óÀâ±â ¼ºÀå
  • centrifugal growth
    ¿ø½É¼º ¼ºÀå
  • controlling factors in facial growth
    ¾È¸é ¼ºÀåÀÇ Á¶Àý ¿äÀÎ
  • deep invasive growth
    ½ÉºÎ ħÀÔ¼º ¼ºÀå
  • eccentric growth
    Æí½É ¼ºÀå
  • endochondral bone growth
    ¿¬°ñ³» °ñ ¼ºÀå
  • exclusively centrifugal growth
    ¹èŸÀû ¿ø½É ¼ºÀå
  • exponential growth
    Áö¼ö Áõ½Ä
  • exponential phase of growth
    ´ë¼ö Áõ½Ä±â, °¡¼Ó ¼ºÀå±â
  • horizontal growth
    ¼öÆò ¼ºÀå
  • human growth hormone
    ¼ºÀå È£¸£¸ó
    ¼ºÀåÀ» ÃËÁøÇÏ´Â ¹°ÁúÀ» ÃÑĪÇϸç, ƯÈ÷ ³úÇϼöü Àü¿±¿¡¼­ ºÐºñµÇ´Â È£¸£¸óÀ» ¸»ÇÑ´Ù.
  • neural growth
    ½Å°æ°èÇü ¼ºÀå
  • no growth
    ¹«¼ºÀå
  • nonbleeding growth
    ºñÃâÇ÷¼º ¼ºÀå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
relative scotoma A scotoma in which there is visual depression but not complete loss of light perception.
(05 Mar 2000)
relative sensitivity The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test.
(05 Mar 2000)
relative specificity The specificity of a medical screening test as determined by comparison with the same type of test (e.g., specificity of a new serological test relative to specificity of an established serological test).
(05 Mar 2000)
relative value scales Coded listings of physician or other professional services using units that indicate the relative value of the various services they perform. They take into account time, skill, and overhead cost required for each service, but generally do not consider the relative cost-effectiveness. Appropriate conversion factors can be used to translate the abstract units of the relative value scales into dollar fees for each service based on work expended, practice costs, and training costs.
(12 Dec 1998)
relative viscosity The ratio of the viscosity of a solution or dispersion to the viscosity of the solvent or continuous phase.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
accretionary growth Growth by an increase of intercellular material.
(05 Mar 2000)
appositional growth Growth accomplished by the addition of new layers on those previously formed; e.g., the addition of lamellae in the formation of bone; it is the characteristic method of growth when rigid materials are involved.
(05 Mar 2000)
auxetic growth Growth by increase in the size of component cells.
Synonym: intussusceptive growth.
(05 Mar 2000)
bacterial growth Growth of a bacterial culture either by increase in cell material or cell number.
(05 Mar 2000)
B-cell differentiation/growth factors Various substances, usually obtained from the supernatant of T-cell cultures, such as interleukin 4, 5, and 6. These substances are necessary for B-cell growth, maturation, and differentiation into plasma cells or B memory cells.
(05 Mar 2000)
biphasic growth curve <cell culture, microbiology> A particular type of growth curve seen in cultured microorganisms in which they have two exponential growth stages separated by a plateau phase. This double-hump curve is produced when the microbes are cultured using two carbon sources, one of which must be used up before the second can be used.
(19 Jan 1998)
bovine growth hormone <endocrinology> A hormone secreted by the bovine pituitary gland. It is used to increase milk production by improving the feed efficiency in dairy cattle.
(14 Nov 1997)
brain-derived growth factor <growth factor> Small basic protein purified from pig brain, a member of the family of neurotrophic factors that also includes Nerve Growth Factor and neurotrophin 3.
In contrast to nerve growth factor, brain-derived neurotrophic factor is predominanantly (though not exclusively) localised in the CNS. It supports the survival of primary sensory neurons originating from the neural crest and ectodermal placodes that are not responsive to NGF.
In the brain brain-derived neurotrophic factor has a trophic action on retinal, cholinergic, and dopaminergic neurons, and in the peripheral nervous system it acts on both motor and sensory neurons.
Acronym: BDGF
(12 Dec 1998)
capon-comb-growth test A test for androgenic activity, based upon the stimulation of comb growth in capons (castrated cockerels) or immature roosters.
Synonym: capon-comb-growth test, cock's comb test.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative adjective
    °ü°è Çü¿ë»ç
  • relative adverb
    °ü°è ºÎ»ç
  • relative aperture
    (¸Á¿ø°æ.Ä«¸Þ¶ó µîÀÇ)±¸°æºñ(aperture ratio)
  • relative biological effectiveness
    »ý¹°ÇÐÀû È¿°úºñ;»ý¹°È¿°úºñ
  • relative clause
    °ü°è»çÀý !
  • relative frequency
    »ó´ëµµ¼ö(ºóµµ)
  • relative humidity
    »ó´ë½Àµµ
  • relative majority
    »ó´ë ´Ù¼ö(¼±°Å¿¡¼­ °ú¹Ý¼ö ¹Ì´ÞÀÎ °æ¿ìÀÇ ¼öÀ§)
  • relative pronoun
    °ü°è ´ë¸í»ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á